Australia markets closed

NeuroBo Pharmaceuticals, Inc. (NRBO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
4.3400-0.2600 (-5.65%)
At close: 04:00PM EDT
4.3500 +0.01 (+0.23%)
Pre-market: 04:04AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 21.19M
Enterprise value -4.42M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.98
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.35

Trading information

Stock price history

Beta (5Y monthly) -0.43
52-week change 3-20.92%
S&P500 52-week change 328.64%
52-week high 37.6000
52-week low 32.8880
50-day moving average 34.5155
200-day moving average 33.9844

Share statistics

Avg vol (3-month) 31.41M
Avg vol (10-day) 389.9k
Shares outstanding 54.91M
Implied shares outstanding 64.91M
Float 84.66M
% held by insiders 138.90%
% held by institutions 11.90%
Shares short (29 Feb 2024) 440.85k
Short ratio (29 Feb 2024) 40.01
Short % of float (29 Feb 2024) 41.23%
Short % of shares outstanding (29 Feb 2024) 40.83%
Shares short (prior month 31 Jan 2024) 426.56k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 331 Dec 2019
Ex-dividend date 4N/A
Last split factor 21:8
Last split date 321 Dec 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 Sept 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-45.76%
Return on equity (ttm)-86.09%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -12.44M
Net income avi to common (ttm)-11.83M
Diluted EPS (ttm)-43.8200
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)25.84M
Total cash per share (mrq)5.32
Total debt (mrq)218k
Total debt/equity (mrq)1.01%
Current ratio (mrq)5.54
Book value per share (mrq)4.49

Cash flow statement

Operating cash flow (ttm)-9.21M
Levered free cash flow (ttm)-2.72M